ID   NCI-N87 HR
AC   CVCL_WH01
SY   NCI N87 HR
DR   cancercelllines; CVCL_WH01
DR   Wikidata; Q95993868
RX   PubMed=26919099;
CC   Doubling time: 26 hours (PubMed=26919099).
CC   Selected for resistance to: DrugBank; DB00072; Trastuzumab (Herceptin).
CC   Sequence variation: Gene deletion; HGNC; 6770; SMAD4; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg248Gln (c.743G>A); ClinVar=VCV000012356; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
DI   NCIt; C5473; Gastric tubular adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1603 ! NCI-N87
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 05-10-23; Version: 8
//
RX   PubMed=26919099; DOI=10.18632/oncotarget.7575;
RA   Arienti C., Zanoni M., Pignatta S., Del Rio A., Carloni S.,
RA   Tebaldi M., Tedaldi G., Tesei A.;
RT   "Preclinical evidence of multiple mechanisms underlying trastuzumab
RT   resistance in gastric cancer.";
RL   Oncotarget 7:18424-18439(2016).
//